Systemic inflammatory markers in individuals with cerebral palsy

Pingel, Jessica; Barber, Lee; Andersen, Ida Torp; Von Walden, Ferdinand; Tierp-Wong, Christian Nai En; Døssing, Simon; Nielsen, Jens Bo

Published in:
European Journal of Inflammation

DOI:
10.1177/2058739218823474

Publication date:
2019

Document Version
Publisher’s PDF, also known as Version of record

Citation for published version (APA):
Systemic inflammatory markers in individuals with cerebral palsy

Jessica Pingel,1 Lee Barber,2 Ida Torp Andersen,1 Ferdinand Von Walden,3 Christian Wong,4 Simon Døssing4 and Jens Bo Nielsen1,5

Abstract
Individuals with cerebral palsy (CP) develop skeletal muscle contractures that impair muscle function. In turn, contractures affect the ability to ambulate and often promote a sedentary lifestyle. The aim of the present study was to investigate the systemic inflammatory markers transforming growth factor beta-1 (TGFβ1), C-reactive protein (CRP), and interleukin-6 (IL-6) in children and adults with CP. Blood samples of n = 34 participants (24 individuals with CP (n = 14 children with CP age 10.36 ± 1.1 and n = 10 adults with CP age 38.80 ± 3.6) and 10 healthy adults age 36.63 ± 3.8) were analyzed for circulating levels of TGFβ1, CRP, and IL-6 using Sandwich Enzyme linked immunosorbent assay (ELISA) analyses (R&D systems). TGFβ1 and CRP levels were significantly higher in children with CP compared to both adults with CP (TGFβ1: P < 0.0005 and P < 0.0002, respectively) and healthy adults (CRP: P < 0.0001 and P < 0.0001, respectively), while no differences were observed between the adults with CP and healthy adults in TGFβ1 (P = 0.29) and CRP (P = 0.59), respectively. Furthermore, IL-6 levels showed no significant differences between the groups. The present findings indicate that the level of systemic inflammation is increased in children with CP. We speculate that persisting inflammation in children with CP might influence the development of muscle contractures, resulting in reduced muscle mass and marked muscle weakness in adults with CP.

Keywords
cerebral palsy, C-reactive protein, inflammation, interleukin-6, muscle, transforming growth factor beta-1

Introduction
Cerebral palsy (CP) describes a spectrum of movement disorders caused by a lesion of the developing brain.1,2 The upper motor neuron lesion impairs neuromotor development2 and results in a cascade of secondary musculoskeletal changes including muscle contractures.1 Contracture development in individuals with CP is progressive and leads to a step-wise reduction in musculoskeletal development, muscle fatigability, and reduced physical activity.2 As a consequence of poor muscle health and a sedentary lifestyle, the prevalence of chronic conditions such as diabetes, hypertension, and arthritis is greater in individuals with CP as compared to typically developed (TD) peers.3 In typically developing individuals, all of these impairments and conditions have been associated with...
elevated circulating systemic inflammatory
markers, which can contribute to the develop-
ment or progression of certain conditions.4

Transforming growth factor beta-1 (TGFβ1) is
one systemic pro-inflammatory cytokine that has
been shown to influence muscle development and
elevated mRNA levels of TGFβ1 and TGFβR2
have been observed in muscle tissue of children
with CP with fixed contractures.5 In addition,
C-reactive protein (CRP) is another important sys-
temic inflammatory marker and indicator of mus-
tle tissue catabolism and previous findings have
shown that CRP might have a direct negative influ-
ence on skeletal muscle cells and underlies the
connection between poor muscle function and sys-
temic inflammation.6 Another pro-inflammatory
cytokine that has received considerable attention in
connection to exercise and muscle growth is inter-
leukin 6 (IL-6), as chronically elevated levels pro-
mote skeletal muscle wasting.7 Early and
accelerated loss of strength and functional capa-
bilities occur in individuals with CP relative to
healthy individuals.8 Little is known about what
factors contribute to the decline. Systemic inflam-
matory cytokines and acute phase proteins may
also affect muscle growth and quality and thus
musculoskeletal development. Therefore, the aim
of this study was to investigate the circulating lev-
els of TGFβ1, CRP, and IL-6 in children and adults
with CP compared to typically developing healthy
individuals.

**Methods**

**Design**

Thirty-four participants (24 individuals with CP
and 10 healthy adult participants) were recruited
to the study. Anthropometric data are presented in
Table 1. Inclusion criteria of the individuals with
CP: (1) clinical diagnosis of CP (brain lesion diag-
nosed within the first 2 years of life); (2) the clini-
cal history of each participant with CP and gross
motor function classification system (GMFCS)
scores are shown in Table 2. Exclusion criteria:
Other brain lesion(s) that have been diagnosed
after the first 2 years of life. The healthy partici-
pants were included in the study if they had no his-
tory of previous musculoskeletal disorders. The
research protocol was approved by the Regional
Ethics Committee for Copenhagen (H-4-2014-
047), in compliance with the Helsinki Declaration.
Participants were recruited via the Orthopedic
Department, University Hospital, Hvidovre,
Denmark, or from the University of Copenhagen.
All adult participants, and parent/guardian of child
participants, gave informed consent to be involved
in the study.

Blood samples were taken from n=14 children
with CP (CP_C), n=10 adults with CP (CP_A),
and n=10 healthy adults (Con_A). All blood sam-
pleS were taken in the morning while the partici-
pant rested in a quiet laboratory room. The blood
samples of children were taken the day before a
planned orthopedic surgery. All children were
examined prior to surgery by the treating surgeon
and considered medically healthy (without any
present cold or flu infections) and able to proceed
to surgery. Blood samples were taken from all
adults with CP were also taken in a non-stressful
environment 1–4 days before a planned orthopedic
surgery, and from all healthy adults after inclusion
in the study. Blood samples were collected using a
butterfly needle (Terumo; cannula 0.8 × 19 mm,
18 cm) from the antecubital vein in one arm and
left on slush ice for 15 min before they were spun
and plasma was removed. The plasma was stored
at −80°C for subsequent Enzyme linked immuno-
sorbent assay (ELISA) analysis.

**ELISA analysis**

Samples were analyzed for TGFβ1, CRP, and IL-6
using a quantitative sandwich enzyme immunoas-
say (all from R&D Systems, Minneapolis, MN,
USA) in accordance with the manufacturer’s recom-
endations. TGFβ1 ELISA: plasma samples were
first activated and then neutralized according to the
manufacturer’s instructions. Samples from all par-
ticipants were analyzed in the same assay. The mini-
imum detectable dose (MDD) ranged from
1.7–15.4 pg/mL, and the intra-assay variation (coef-
efficient of variation) was 2.7%. Human CRP ELISA:
plasma samples were diluted 100-fold according to

**Table 1. Subject characteristics.**

<table>
<thead>
<tr>
<th></th>
<th>Age (year)</th>
<th>Height (m)</th>
<th>Weight (kg)</th>
<th>BMI (kg/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP children</td>
<td>10.36 ± 1.1</td>
<td>1.4 ± 0.1</td>
<td>34.8 ± 2.9</td>
<td>17.7 ± 0.7</td>
</tr>
<tr>
<td>CP adults</td>
<td>38.80 ± 3.6</td>
<td>1.7 ± 0.1</td>
<td>72.5 ± 3.4</td>
<td>26.4 ± 1.6</td>
</tr>
<tr>
<td>Con adults</td>
<td>36.63 ± 3.8</td>
<td>1.8 ± 0.1</td>
<td>77.0 ± 3.1</td>
<td>24.5 ± 0.6</td>
</tr>
</tbody>
</table>

BMI: body mass index; CP: cerebral palsy.
All data shown in mean ± SEM.
### Table 2. Clinical history of all patients.

<table>
<thead>
<tr>
<th>Subject</th>
<th>GMFCS</th>
<th>Gender</th>
<th>Classification</th>
<th>Operation</th>
<th>Previous Btx treatment</th>
<th>Oral antispastic treatment</th>
<th>Ambulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP child 1</td>
<td>1</td>
<td>F</td>
<td>Hemiplegic</td>
<td>Bilateral calf muscle elongation</td>
<td>Once 2 years before the study without effect</td>
<td>Baclofen</td>
<td>yes with orthosis</td>
</tr>
<tr>
<td>CP child 2</td>
<td>1</td>
<td>M</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation (twice)</td>
<td>No</td>
<td>No</td>
<td>yes</td>
</tr>
<tr>
<td>CP child 3</td>
<td>1</td>
<td>F</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation</td>
<td>No</td>
<td>No</td>
<td>yes</td>
</tr>
<tr>
<td>CP child 4</td>
<td>1</td>
<td>F</td>
<td>Hemiplegic</td>
<td>Unilateral calf muscle elongation</td>
<td>No</td>
<td>No</td>
<td>yes</td>
</tr>
<tr>
<td>CP child 5</td>
<td>1</td>
<td>M</td>
<td>Hemiplegic</td>
<td>Unilateral calf muscle elongation</td>
<td>Regular calf and hand treatments</td>
<td>No</td>
<td>yes with orthosis</td>
</tr>
<tr>
<td>CP child 6</td>
<td>4</td>
<td>M</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation</td>
<td>Regular calf, hamstring, and hand treatments</td>
<td>Baclofen</td>
<td>yes with orthosis and walker</td>
</tr>
<tr>
<td>CP child 7</td>
<td>4</td>
<td>M</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation</td>
<td>Regular calf and hand treatments</td>
<td>Baclofen</td>
<td>yes with orthosis and walker</td>
</tr>
<tr>
<td>CP child 8</td>
<td>3</td>
<td>M</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation</td>
<td>Once several years before the study without effect</td>
<td>No</td>
<td>yes with orthosis</td>
</tr>
<tr>
<td>CP child 9</td>
<td>2</td>
<td>F</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation (twice)</td>
<td>Once several years before the study without effect</td>
<td>No</td>
<td>yes with orthosis</td>
</tr>
<tr>
<td>CP child 10</td>
<td>1</td>
<td>F</td>
<td>Hemiplegic</td>
<td>Unilateral calf muscle elongation (twice)</td>
<td>A few times several years before the study without effect</td>
<td>No</td>
<td>yes with orthosis</td>
</tr>
<tr>
<td>CP child 11</td>
<td>5</td>
<td>F</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation and hip surgery</td>
<td>Regular calf and hand treatments</td>
<td>Baclofen</td>
<td>No but stands with walker</td>
</tr>
<tr>
<td>CP child 12</td>
<td>4</td>
<td>M</td>
<td>Tetraplegic</td>
<td>Bilateral calf muscle elongation and hip surgery</td>
<td>Regular treatments at several sites in both upper and lower limbs</td>
<td>Baclofen pump</td>
<td>yes but only little with orthosis and walker</td>
</tr>
<tr>
<td>CP child 13</td>
<td>3</td>
<td>M</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation (several times)</td>
<td>No</td>
<td>No</td>
<td>yes with orthosis</td>
</tr>
<tr>
<td>CP child 14</td>
<td>4</td>
<td>F</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation (twice) and hamstring surgery</td>
<td>Regular calf and hamstring treatments</td>
<td>Baclofen</td>
<td>yes with orthosis and walker</td>
</tr>
<tr>
<td>CP adult 1</td>
<td>4</td>
<td>F</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation (twice) and hamstring surgery</td>
<td>No</td>
<td>Baclofen</td>
<td>yes</td>
</tr>
<tr>
<td>CP adult 2</td>
<td>2</td>
<td>M</td>
<td>Hemiplegic</td>
<td>–</td>
<td>No</td>
<td>No</td>
<td>yes</td>
</tr>
<tr>
<td>CP adult 3</td>
<td>1</td>
<td>F</td>
<td>Hemiplegic</td>
<td>Unilateral calf muscle elongation</td>
<td>Yes regular treatments</td>
<td>No</td>
<td>yes</td>
</tr>
<tr>
<td>CP adult 4</td>
<td>1</td>
<td>M</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation</td>
<td>No</td>
<td>No</td>
<td>yes</td>
</tr>
<tr>
<td>CP adult 5</td>
<td>1</td>
<td>M</td>
<td>Hemiplegic</td>
<td>Bilateral calf muscle elongation and hamstring surgery</td>
<td>No</td>
<td>No</td>
<td>yes</td>
</tr>
<tr>
<td>CP adult 6</td>
<td>1</td>
<td>F</td>
<td>Diplegic</td>
<td>Bilateral calf muscle elongation and hip surgery</td>
<td>No</td>
<td>Baclofen</td>
<td>yes</td>
</tr>
<tr>
<td>CP adult 7</td>
<td>1</td>
<td>M</td>
<td>Hemiplegic</td>
<td>Bilateral calf muscle elongation and hamstring surgery</td>
<td>No</td>
<td>Aprofopam</td>
<td>yes</td>
</tr>
</tbody>
</table>

(Continued)
the protocol. Samples from all participants were analyzed in the same assay. The MDD ranged from 0.005–0.022 ng/mL, and the intra-assay variation (coefficient of variation) was 5.5%. One CP-C sample was under the detectable range and the data were not included in the statistical analysis. IL-6 ELISA: MDD was less than 0.70 pg/mL, and the intra-assay variation (coefficient of variation) was 2.6%. In total, six samples were under the detectable range and not included in the statistical analysis. Final participant data included in analysis were CP_C, n = 11 (three missing samples); CP_A, n = 8 (two missing samples); and Con_A, n = 9 (one missing sample).

Statistics
All data are presented as mean ± SEM. Non-parametric unpaired t-tests were used to analyze differences between the CRP, TGFβ1, and IL-6 levels of the three groups. The level of significance was P < 0.05. All statistical analyses and Figure 1 were generated in GraphPad Prism 6.04 (GraphPad Software, Inc., San Diego, CA, USA).

Results
TGFβ1 levels were significantly higher in children with CP (13.21 ± 2.31 pg/mL) compared to both adults with CP (7.91 ± 2.11 pg/mL; P < 0.0001) and healthy adults (6.89 ± 2.66 pg/mL; P < 0.0001) (Figure 1(a)). No differences were observed between adults with CP and healthy adults (P = 0.588). In the assay description from R&D systems, the normal level of TGFβ1 is stated to be lower than detection limit mean of 1165 pg/mL (measured in n = 23 healthy individuals).

The CRP levels of the children with CP (57.22 ± 17.98 ng/mL) were significantly higher when compared to both adults with CP (7.91 ± 2.11 ng/mL; P < 0.0001) and healthy adults (6.89 ± 2.66 ng/mL; P < 0.0001) (Figure 1(b)). No differences were observed between adults with CP and healthy adults (P = 0.588). In the assay description from R&D systems, the normal level of CRP is stated to be lower than detection limit mean of 1547 ng/mL (measured in n = 35 healthy individuals).

The IL-6 levels were also higher but not significant in children with CP (2.61 ± 1.06 pg/mL) compared to both adult groups (adults with CP: 1.44 ± 0.49 pg/mL (P < 0.5916); healthy control adults: 1.25 ± 0.77 pg/mL (P < 0.51) (Figure 1(c))). In the assay description from R&D systems, it is stated the normal level of IL-6 in n = 33 healthy individuals was measured to be lower than detection limit (3.13 pg/mL), while n = 7 further individuals had IL-6 levels that ranged from 3.13 to 12.5 pg/mL.

Discussion
The present study shows that children with CP have significantly higher systemic levels of TGFβ1 and CRP, when compared to adults with CP and healthy adults and also when compared to TD child normative values.9 Persistent or recurrent elevated blood concentrations of inflammation-related proteins during the first two postnatal weeks in preterm infants are associated with CP10; however, little is known about elevated systemic inflammation and the effects thereof on neurological and/or musculoskeletal development of school-age children with CP. All children that were included in the present...
study had muscle contractures and needed surgical corrections. It may be speculated that elevated levels of multiple systemic inflammatory markers in this group of children were related to skeletal muscle contractures. Systemic inflammation may be the consequence of the muscle tissue attempting to repair muscle damage following chronic overload.\textsuperscript{11} In the growing muscle tissue of children with CP, systemic inflammation may also contribute to the failure of normal hypertrophic growth and tissue remodeling through a reduction of protein synthesis rate as previously observed in muscular dystrophies.\textsuperscript{12} Elevated levels of TGFβ1, CRP, and IL-6 have been accompanied by reduced muscle mass,\textsuperscript{7} indicating a catabolic effect of inflammation on muscle tissue. However, the present study can unfortunately not conclude any cause and effect relationship between systemic inflammation and severity of muscle contractures. The relationship between the severity of the brain lesion causing CP (as indicated by brain magnetic resonance imaging (MRI)) and levels of systemic inflammation may offer promising opportunities for future studies. One major drawback of the current study is the lack of blood samples from TD children. Therefore, the results from the present study cannot rule out that a general difference exists in inflammatory levels between children and adults, or individuals with differing levels of activity. However, all of our participants were considered medically healthy (no current infections/medical disorders); therefore, any systemic inflammation was expected to be very low. Furthermore, in order to limit stress prior to surgery as a confounding factor, the blood samples have been taken at least 1 day before the surgical intervention. The present study shows that systemic levels of TGFβ1 and CRP are significantly increased in children with CP when compared to healthy adults and adults with CP. An inclusion of blood samples from TD children and CP children without muscle contractures and children who have different neuromuscular disorders might offer interesting and important extensions of this study.

**Acknowledgements**

All authors have contributed equally to this work and have approved the final version of the manuscript. All authors are designated as authors and are qualified for authorship, and are all listed as authors.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was funded by the Danish research Council (DFF-1333-00197) and the Elsass Foundation.

ORCID iD
Jessica Pingel https://orcid.org/0000-0002-9977-094X

References